Here's a summary list I made while reading the whole thread:
finance.yahoo.com
ACLA aclara.com Market Capitalization $62.3M Total Cash (mrq) $76.2M
Aclara Biosciences, Inc. is a microfluidics, or lab-on-a-chip, company with access to a wide range of technology and intellectual property required to broadly address the genomics and pharmaceutical drug screening markets. The Company is developing multiple products based on its proprietary microfluidics and chemistry-based technologies that allow researchers to rapidly perform large numbers of chemical and biological measurements in a multiplexed, automatable format. The Company's Arteas and Plurex microfluidic Labcard products and eTag assay chemistries are designed to function on multiple existing instrument platforms and to leverage the substantial installed base of such instrumentation.
ARNA arenapharm.com Market Capitalization $193.6M Total Cash (mrq) $215.2M
Arena Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused principally on discovering and developing drugs that target G protein-coupled receptors, called GPCRs. GPCRs are an important part of the pharmaceutical and biotechnology industries' drug discovery and development efforts. Many pharmaceutical products wholly, or in part, act on GPCRs. The Company has developed a technology called constitutively activated receptor technology (CART), a new technology that it uses to identify drug leads more efficiently than traditional drug discovery techniques.
CALP calipertech.com Market Capitalization $157.9M Total Cash (mrq) $151.3M
Caliper Technologies Corp. is active in lab-on-a-chip technologies. The Company has developed three types of LabChip systems, based on distinct chip formats: personal laboratory systems, high-throughput systems and application development systems. The Company's personal laboratory systems use chips with reservoirs for the various chemical reagents, which the user introduces manually. Caliper Technologies' high-throughput systems use its sipper chip systems, which have a short tube that draws nanoliter volumes of reagents into the chip. The Company's application development system is a microscope-based instrument that uses chips capable of performing many different analytical experiments, also known as assays, and analyses.
CRA celera.com Market Capitalization $747.4M Total Cash (mrq) $908.6M
Celera Genomics, a business of Applera Corp., conducts its business through two groups: the Applied Biosystems Group (Applied Biosystems), which is engaged principally in the development, manufacture, sale, and service of instrument systems and associated consumable products for life science and related applications; and the Celera Genomics Group (Celera Genomics), which is engaged principally in integrating high throughput technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera Genomics' businesses are its online information business and its therapeutic discovery business.
CRGN curagen.com Market Capitalization $248.8M Total Cash (mrq) $478.1M
CuraGen Corporation is a genomics-based pharmaceutical development company that applies its integrated functional genomic technologies and Internet-based bioinformatic systems to discover and develop pharmaceutical products to treat large unmet medical needs. Through the application of its proprietary technologies, the Company is gaining an understanding of how genes and proteins function in the context of disease, and is applying this knowledge to the development of protein, antibody and small molecule therapeutics. The Company's integrated functional genomic technologies are enabling its scientists to conduct research throughout each stage of the drug discovery, drug development and pharmacogenomics screening and evaluation process. The Company has established internal programs to develop products to treat metabolic diseases, cancer, inflammatory diseases and central nervous system disorders.
CTIC cticseattle.com Market Capitalization $163.6M Total Cash (mrq) $236.0M
Cell Therapeutics, Inc., incorporated in 1991, develops, acquires and commercializes novel treatments for cancer. The Company's goal is to build a vertically integrated biopharmaceutical company with a diversified portfolio of proprietary oncology drugs. CTI, CT-2584 and Trisenox are the Company's trademarks. The Company's lead product is Trisenox, which is marketed for patients with acute promyelocytic leukemia.
CVAS corvas.com Market Capitalization $54.5M Total Cash (mrq) $85.4M
Corvas International, Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of cardiovascular disease and cancer. The Company's partner, Pfizer, has completed patient enrollment in a Phase IIb clinical trial of its lead product candidate, a recombinant protein, UK-279,276, formerly recombinant neutrophil inhibitory factor (rNIF). Results from this efficacy study of UK-279,276 for the treatment of reperfusion injury associated with ischemic stroke, conducted by Pfizer, are expected to be available in mid-2002. Corvas is developing its second lead product candidate, a novel proprietary injectable anticoagulant, recombinant NAPc2 (rNAPc2), for the treatment of acute coronary syndromes, which include unstable angina. In anticipation of studies in unstable angina, the Company has completed a Phase IIa safety study in patients undergoing elective coronary angioplasty.
DDDP 3dp.com Market Capitalization $92.1M Total Cash (mrq) $93.7M
3-Dimensional Pharmaceuticals, Inc. is a small-molecule drug discovery and development business that has a pipeline of drug candidates in the areas of cancer, inflammation and metabolic and cardiovascular diseases. All of the drug candidates in the Company's pipeline were discovered using all or a major portion of its integrated set of proprietary technologies, DiscoverWorks. DiscoverWorks may also enable 3-Dimensional to discover drugs that act on many of the thousands of new drug targets revealed from sequencing the human genome. The Company uses DiscoverWorks to discover and develop drugs for its own pipeline and in collaboration with pharmaceutical and biotechnology companies.
EMIS emisphere.com Market Capitalization $59.8M Total Cash (mrq) $87.4M
Emisphere Technologies, Inc. is a biopharmaceutical company engaged in solving one of the most challenging technical hurdles in the pharmaceutical industry: the oral delivery of medicines, which, for a variety of reasons, cannot be offered to patients directly in an oral form. The Company has pioneered the oral delivery of otherwise injectable drugs, including proteins, peptides, polysaccharides and other compounds not currently deliverable by oral means. These drugs present challenges for oral delivery because they are often large molecules (macromolecules), which are inactivated in the gastrointestinal tract, have limited ability to cross cell membranes and generally cannot be delivered orally.
ETRX microcide.com Market Capitalization $31.6M Total Cash (mrq) $52.7M
Essential Therapeutics, Inc., formerly Microcide Pharmaceuticals, Inc., is a biopharmaceutical company that discovers, develops and commercializes critical products for life-threatening diseases in hematology, oncology and infectious disease. It also has pre-clinical and clinical programs in hematology/oncology and infectious diseases. Essential's lead product, ETRX 101, is a small-molecule angiotensin derivative for treatment and prophylaxis of the suppression of blood cells, known as myelosuppression, and other serious clinical diseases. The Company has the Novel Cephalosporin Platform, which targets serious gram-positive multi-drug resistant infections, Efflux Pump Inhibitor Platform for gram-negative infections, as well as serious fungal infections and the Structure-Based Drug Design Platform, focusing on novel cell wall biosynthesis inhibitors, with intrinsic activity against a broad spectrum of resistant organisms.
GNSC genaissance.com Market Capitalization $22.3M Total Cash (mrq) $50.1M
Genaissance Pharmaceuticals, Inc. is engaged in the creation of personalized medicines through the integration of gene variation into drug development. The Company uses its technological capabilities and methods and its clinical genetics development skills to identify the genomic markers that appear to define a patient population that responds best to a medication and has a superior safety profile. It intends to create new therapeutic products for these patient populations by changing the formulation of existing drugs, as well as by completing the development of drugs through joint ventures and license agreements. Genaissance markets its technology and genomic markers to the pharmaceutical and biotechnology industry as a means to improve the development, marketing and prescribing of drugs.
IMGN immunogen.com Market Capitalization $83.1M Total Cash (mrq) $144.0M
ImmunoGen, Inc. is a developer of antibody-based cancer therapeutics. The Company's proprietary, tumor-activated pro-drug (TAP) technology combines extremely potent, small-molecule drugs with monoclonal antibodies that recognize and bind directly to tumor cells. The Company is testing its two most advanced product candidates, huC242-DM1/SB-408075 and huN901-DM1/BB-10901, as single agents in patients with colon, pancreatic and non-small-cell lung cancer and small-cell lung cancer, respectively. Each TAP consists of an antibody that is chemically linked, or conjugated, to a small molecule drug that serves as an effector molecule. The antibodies ImmunoGen uses target and bind specifically to antigens that are primarily found on certain types of cancer cells. Once bound to the cell surface, the cell internalizes the Company's TAP, triggering the release of the effector molecules that then kill the cancer cell.
INCY incyte.com Market Capitalization $399.2M Total Cash (mrq) $491.7M
Incyte Genomics, Inc. designs, develops and markets genomic information-based tools, including information databases, data management tools, gene expression services and related services. The Company has a commercial portfolio of issued United States patents covering human, full-length genes, the proteins they encode and the antibodies directed against them. Incyte has developed an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. These technologies primarily consist of genomic databases and pharmaceutically relevant intellectual property licenses, which help pharmaceutical and biotechnology researchers in their therapeutic discovery and development efforts. The Company's current products include information databases, intellectual property licensing and certain other products, such as full-length clones.
INGN introgen.com Market Capitalization $43.8M Total Cash (mrq) $41.7M
Introgen Therapeutics Inc. (Introgen) is a developer of gene therapy products for the treatment of cancer. Introgen is capitalizing on the significant advances in the understanding of the human genome and the role that genetic function plays in the development of cancer and other diseases. The Company's drug discovery and development programs have resulted in new approaches by which physicians use genes to treat cancer and other diseases. The Company's products include INGN 201 (p53), INGN 241 (mda-7), INGN 251 (PTEN), BAK program and P16 program.
INMX informaxinc.com Market Capitalization $21.9M Total Cash (mrq) $57.2M
Informax, Inc. is a global provider of informatic software solutions to the life sciences industry. Informatics applies the power and dramatic advances that have taken place in mathematical, computer and life sciences to accelerate and enhance the research of scientific communities. Its integrated solutions strategy, called High-Throughput Research (HTR), combines software solutions, consulting services and scientific expertise to provide the enabling technology for drug discovery and development customers. The Company's HTR approach enables scientists to increase the effectiveness of their research and reduce the time and cost of identifying and validating biological targets for pharmaceutical, therapeutic and diagnostic development. Its portfolio of informatic software solutions help scientists manage, analyze and interpret the enormous amount of genomic, proteomic and other biomolecular data generated in recent years.
KDUS.ob cadus.com Market Capitalization $15.1M Total Cash (mrq) $24.9M
Cadus Pharmaceutical Corporation (Cadus) develops technologies based on yeast that are useful in identifying drug discovery candidates targeted at G Protein-coupled receptors. The genes in yeast express proteins, including cell-surface receptors such as G Protein-coupled receptors, as well as signaling molecules such as protein kinases, which are similar to human proteins. The Company has developed several drug discovery technologies that address many of the limitations of traditional drug discovery methods, including tools used to screen for compounds that act as agonists or antagonists to cell surface receptors, and tools used to identify ligands to targeted orphan receptors. Cadus has also developed a proprietary technology to insert human genes into yeast cells to create hybrid yeast cells. In December 2001, the Company transferred all of its patents, patent applications, know how, licenses and drug discovery technologies to its wholly owned subsidiary, Cadus Technologies, Inc.
LSBC lsbc.com Market Capitalization $39.9M Total Cash (mrq) $41.2M
Large Scale Biology Corporation develops therapeutic products using its proprietary technology and expertise in proteins. The Company has technological expertise in three areas: proteomics, the study of proteins and how they change in disease and in response to drugs, functional genomics, the study of each protein's function and the production of proteins for commercial applications. The Company focuses on three main product categories: cancer vaccine immunotherapy and development of other vaccines for the treatment and prevention of infectious diseases, products and processes for treatment of a variety of diseases in the medical field of hematology and the low-cost production of complex human proteins in genetically engineered host plants for its products and in partnership with others. The Company's core technology, Geneware, is a modified viral vector system used to insert genes rapidly and temporarily into host organisms, usually plants in the Nicotiana species.
MAXM maxim.com Market Capitalization $76.6M Total Cash (mrq) $124.6M
Maxim Pharmaceuticals, Inc. is a global bio-pharmaceutical company with a diverse pipeline of therapeutic candidates for life-threatening cancers and hepatitis. The Company's lead drug candidate Ceplene (histamine dihydrochloride) is designed to prevent or reverse damage associated with oxidative stress, thereby protecting immune cells and other critical cells and tissue. Because Ceplene impacts basic immune functions, it has the potential to be used in a broad range of diseases in which oxidative stress plays an important role. More than 1,300 patients have participated in the Company's 15 completed and ongoing clinical trials of Ceplene in the following diseases: life-threatening cancers, such as advanced metastatic melanoma (the most deadly form of skin cancer), acute myelogenous leukemia and renal cell carcinoma (kidney cancer); and Hepatitis C, the most common blood-borne virus in the United States.
NGEN nanogen.com Market Capitalization $63.9M Total Cash (mrq) $59.5M
Nanogen, Inc. is a provider of molecular diagnostic tests. The Company integrates advanced microelectronics and molecular biology into a core technology platform with potentially broad and diverse commercial applications. Nanogen's primary areas of focus have been in genomics and biomedical research, medical diagnostics, forensics and drug discovery. The first application the Company has developed, the NanoChip System, is an integrated bioassay system, consisting of the NanoChip Molecular Biology Workstation and the NanoChip Cartridge. The NanoChip(r) Workstation is comprised of two automated instruments, and the NanoChip Cartridge, a consumable cartridge, incorporates a proprietary microchip. The NanoChip System provides a flexible tool for the rapid identification and precision analysis of biological test samples containing charged molecules.
OGSI ogs.com Market Capitalization $205.6M Total Cash (mrq) $269.8M
Oxford GlycoSciences plc is engaged in proteomics (the study of proteins), which it has integrated with genomics to create a new drug discovery platform. The Company's drug discovery platform allows the systemic separation, identification and characterization of proteins on an industrial scale. The Company's goal is to use the platform to enable the development of a new generation of products by building a pipeline of proprietary small molecule and antibody drug and diagnostic products based on a portfolio of patent applications relating to, or to the use of, disease-associated proteins and providing proteomics services and data to the pharmaceutical and life sciences industries.
PRCS praecis.com Market Capitalization $161.9M Total Cash (mrq) $256.9M
Praecis Pharmaceuticals Incorporated is a drug discovery and development company with a lead product candidate, Plenaxis (abarelix for injectable suspension), for the treatment of hormonally responsive advanced prostate cancer. In December 2000, the Company submitted to the Food and Drug Administration (FDA) a new drug application (NDA) for Plenaxis for the treatment of hormonally responsive advanced prostate cancer. In response to concerns raised by the FDA in June 2001, the Company initiated an additional clinical trial to study the effects of using available hormonal therapies in prostate cancer patients following treatment with Plenaxis. The Company is also evaluating the rare allergic reactions that occurred in clinical trials. Assuming positive results, the Company expects to submit to the FDA additional data by the end of the first quarter of 2003.
RZYM rpi.com Market Capitalization $23.0M Total Cash (mrq) $28.7M
Ribozyme Pharmaceuticals, Inc. is developing a new class of therapeutics based on engineered molecules called ribozymes. The Company uses ribozymes for target discovery and validation to help companies in the life science industry identify genes that cause or contribute to human disease. Ribozymes also have shown applicability in the area of molecular diagnostics. In May 2001, the Company entered into a collaborative agreement with Archemix, a privately held company whose primary technology, RiboReporters, incorporates allosteric ribozymes, which are ribozymes that are active only in the presence of a specific molecule. This technology allows researchers to detect individual molecules in complex mixtures, facilitating the discovery and validation of new drug targets. In addition, ribozymes can be used to identify gene function and to validate the disease-contributing function of a specific gene. In this way, ribozymes can be used to assist in the identification of new drug candidates.
TTP titanpharm.com Market Capitalization $87.3M Total Cash (mrq) $96.0M
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases. Its product offerings include the Iloperidone for chizophrenia and related psychotic disorders; Spheramine for Parkinson's disease; implantable therapeutic systems; CeaVac, TriAb and TriGem immunotherapeutics; Pivanex; Gallium Maltolate, and the RB94 Therapy. The Company is independently developing its product candidates and also utilizing strategic partnerships, including collaborations with Novartis Pharma AG and Schering AG. Some of its pre-clinical product development work is conducted through its two consolidated subsidiaries, Ingenex, Inc. and ProNeura, Inc.
VGNX variagenics.com Market Capitalization $27.1M Total Cash (mrq) $68.5M
Variagenics, Inc. is engaged in applying pharmacogenomics technology to the discovery, development and commercialization of personalized drugs and molecular diagnostic products. The Company's primary therapeutic focus is cancer. Pharmacogenomics is the study of the correlation between an individual's genetic differences or genetic variability and his or her specific response to a drug. The most common form of this genetic variability is a single nucleotide polymorphism (SNP). Using a drug pathway approach, Variagenics identifies therapeutically important genetic markers, including SNPs, groups of SNPs (haplotypes) and other markers. The Company uses its pharmacogenomics technology to select an optimal set of these genetic markers for clinical testing, and, ultimately, the development of high-value molecular diagnostic products, which predict patient response to drugs.
VICL vical.com Market Capitalization $97.2M Total Cash (mrq) $127.4M
Vical Incorporated is focused on the development of biopharmaceutical products based on its patented gene delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the Company's gene delivery technology include gene therapies for cancer, DNA vaccines for infectious diseases or cancer, and DNA therapeutic protein delivery. The Company has a number of therapeutic protein and vaccine product candidates that are currently under its independent and collaborative product development programs. The Company's current clinical development focus is on the cancer therapies, Allovectin-7 and Leuvectin.
VPHM viropharma.com Market Capitalization $28.9M Total Cash (mrq) $213.9M
ViroPharma Incorporated is a pharmaceutical company dedicated to the commercialization, development and discovery of new antiviral medicines. The Company has focused its product development and discovery activities on a number of ribonucleic acid (RNA) virus diseases, including viral respiratory infection (VRI), often referred to as the common cold. Other disease in which ViroPharma focuses its product development activities on include respiratory syncytial virus disease (RSV) and hepatitis C. Picovir (pleconaril) is the Company's most advanced product candidate for the treatment of common diseases caused by picornaviruses. ViroPharma is also developing VP14637, a proprietary small molecule that has been demonstrated to inhibit RSV replication in vitro. The Company has halted the development of VP 50406 after preliminary studies showed that the compound did not demonstrate the desired level of antiviral activity against hepatitis C.
Note: Company descriptions & financials courtesy of Yahoo. |
